Human Genome (HGSI) Announces Results of HGS-ETR1 Phase 2; Shows No Difference from Mapaumumab Vs. Control Group
Tweet Send to a Friend
Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
